ReviewTrends in cancer2018
Challenging Standard-of-Care Paradigms in the Precision Oncology Era.
Review in Trends in cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects.Signal transduction and targeted therapy · 2026Review
- Introducing Precision Medicine into an Undergraduate Medical Curriculum: An Interactive Lecture and Case-Based Learning Activity.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- The Knowledge Connector decision support system for multiomics-based precision oncology.Nature communications · 2026Article
- The Multifaceted Roles of STAT6: Implications for Precision Immunotherapeutics.ImmunoTargets and therapy · 2026Review
- Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials.NPJ precision oncology · 2025Article
- Cancer treatment paradigms in the precision medicine era.Nature medicine · 2025Article
- Large language model processing capabilities of ChatGPT 4.0 to generate molecular tumor board recommendations-a critical evaluation on real world data.The oncologist · 2025Article
- Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.JCO precision oncology · 2025Article
- Tissue-agnostic cancer therapies: promise, reality, and the path forward.Nature communications · 2025Article
- Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial.Journal of immunotherapy and precision oncology · 2025Article
- Single-arm clinical trials: design, ethics, principles.BMJ supportive & palliative care · 2024Review
- Precision Oncology in Older Cancer Patients: A Single-Center Experience.International journal of molecular sciences · 2024Article
- Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.Annals of hematology · 2024Review
- Anticancer drugs: How to select small molecule combinations?Trends in pharmacological sciences · 2024Review
- Prognosis value of heat-shock proteins in esophageal and esophagogastric cancer: A systematic review and meta-analysis.World journal of gastrointestinal oncology · 2024Article
- Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown.Molecular oncology · 2024Article
- Molecular diagnostics tailoring personalized cancer therapy-an oncologist's view.Virchows Archiv : an international journal of pathology · 2024Review
- My battle with cancer. Part 1.Oncoscience · 2024Review
- Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype?Indian journal of surgical oncology · 2023Review
- Implementing precision oncology for sarcoma patients: the CCCJournal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized drug combinations, rather than one-size-fits-all monotherapy. The raison-d'être of precision oncology is to offer 'the right drug for the right patient at the right time', a process enabled by transformative tissue and blood-based genomic technologies. Genomically targeted therapies are most suitable in early disease, when molecular heterogeneity is less pronounced, while immunotherapy is most effective against tumors with unstable genomes. Next-generation cancer research/practice models will need to overcome the tyranny of tradition and emphasize an innovative, precise and personalized patient-centric approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.